[Cytoprotective effect of rosaprostol during treatment with non-steroidal anti-inflammatory agents in arthrorheumatic pathologies].
A clinico-endoscopic study has been carried out in a group of 22 patients treated with 1 g of naproxene + 2 g of rosaprostol compared in a blind situation with another group of 19 patients treated with a similar dose of naproxene + placebo in order to evaluate the cytoprotective action of rosaprostol. Analysis of the results showed a high correlation between intake of rosaprostol and low onset of algico-dyspeptic disturbances and mucosal lesions of some gravity, although the problem of the monitoring of patients undergoing long-term treatment with NSAID remains unsolved.
Cataldo
M G
MG
Sallì
L
L
Scalici
G
G
D'Aiuto
A
A
Bongiorno
A
A
Salerno
L
L
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D004341:Drug Evaluation; D005227:Fatty Acids / Q000627:therapeutic use*; D005260:Female; D005753:Gastric Mucosa; D006801:Humans; D008297:Male; D008875:Middle Aged; D011466:Prostanoic Acids / Q000627:therapeutic use*; D013272:Stomach Diseases / Q000139:chemically induced / Q000517:prevention & control
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005227:Fatty Acids; D011466:Prostanoic Acids; C035288:rosaprostol
L'azione citoprotetiva del rosaprostol in corso di trattamento con FANS in patologie artroreumatiche.